Rein Therapeutics, Inc. Common Stock RNTX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Cost of Goods Sold by Product | ||||||
| License And Maintenance | $35K0.0% | $35K0.0% | $35K-43.5% | $35K-77.3% | $35K-77.3% | |
| License | $25K— | $25K— | —— | —— | —— | |
| Research And Development Expense by Product | ||||||
| Clinical Operation Activities | $5.57M+56.8% | $4.29M+9.5% | $4.21M+34.2% | $5.03M+138% | $3.56M+121% | |
| CMC Activities | $2.2M-38.5% | $2.24M-49.5% | $1.84M-57.4% | $2.52M-26.4% | $3.57M+126% | |
| Employee Related Expenses | $2M-9.9% | $2.12M-3.7% | $2.23M+17.5% | $2.27M+34.8% | $2.22M+46.1% | |
| Facilities And Other Expenses | $83K+36.1% | $74K+57.4% | $74K+61.7% | $70K+86.7% | $61K+63.8% | |
| Professional Fees For Services | $27K— | $44K— | —— | —— | —— | |
| General And Administrative Expense by Product | ||||||
| Employee Related Expenses | $3.66M-29.8% | $3.75M-31.4% | $3.4M-38.7% | $3.61M-29.2% | $5.21M+60.8% | |
| Facilities And Other Expenses | $2M-3.3% | $1.96M-8.3% | $1.99M-4.5% | $1.92M-8.6% | $2.07M+19.8% | |
| Professional Fees For Services | $4.84M-10.2% | $5.19M-17.0% | $6.02M-8.6% | $4.43M-41.1% | $5.39M-26.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rein Therapeutics, Inc. Common Stock break its business down?
- Rein Therapeutics, Inc. Common Stock (RNTX) reports cost of goods sold by product across 2 parts — License And Maintenance and License. Each is extracted from the segment footnotes and tracked over time.
- Where does Rein Therapeutics, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rein Therapeutics, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.